KeyBanc Maintains Buy Rating and Raises Price Target on HCA Healthcare
KeyBanc analyst Matthew Gillmor has maintained a buy rating on HCA Healthcare while increasing the price target to $490.
Stocks · News reference
Analysts Adjust Price Targets for HCA Healthcare
Multiple financial institutions, including Jefferies, BofA, and KeyBanc, updated their price targets for HCA Healthcare on October 28, 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Keybanc Maintains Overweight on HCA Healthcare, Raises Price Target to $490
HCA Healthcare Analysts Raise Their Forecasts Following Better-Than-Expected Q3 Results
HCA Healthcare beat Q3 estimates: revenue rose 3.6% to $19.85B, EPS hit $7.22, and FY26 guidance increased; analysts raised price targets.